Skip to main content

Advertisement

SpringerLink
Log in

Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications

  • INTRODUCTION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Heinrich-Heine University, Department of Neurology, Düsseldorf, Belgium

    Hans-Peter Hartung MD

  2. Central Laboratory Animal Institute and Department of Innovation Studies, Utrecht University, Utrecht, The Netherlands

    Huub Schellekens MD

  3. The Jacobs Neurological Institute, Buffalo General Hospital, Buffalo, New York, USA

    Frederick E. Munschauer III MD

  4. Department of Neurology, Heinrich-Heine University, Moorenstrasse 5, 40225, Düsseldorf, Germany

    Hans-Peter Hartung MD

Authors
  1. Hans-Peter Hartung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huub Schellekens MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frederick E. Munschauer III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Peter Hartung MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartung, HP., Schellekens, H. & Munschauer, F.E. Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications. J Neurol 251 (Suppl 2), ii1–ii3 (2004). https://doi.org/10.1007/s00415-004-1201-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-004-1201-x

Keywords

Search

Navigation